Evidence on the cost of breast cancer drugs is required for rational decision making.

about

Evidence on the cost of breast cancer drugs is required for rational decision making.

Item

http://www.wikidata.org/entity/Q55021818

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Evidence on the cost of breast cancer drugs is required for rational decision making.

@en

Evidence on the cost of breast cancer drugs is required for rational decision making.

@nl

type

Item

label

Evidence on the cost of breast cancer drugs is required for rational decision making.

@en

Evidence on the cost of breast cancer drugs is required for rational decision making.

@nl

prefLabel

Evidence on the cost of breast cancer drugs is required for rational decision making.

@en

Evidence on the cost of breast cancer drugs is required for rational decision making.

@nl

P1476

Evidence on the cost of breast cancer drugs is required for rational decision making.

@en

P2093

Anne Margreet Sofie Berghuis

http://www.w3.org/2001/XMLSchema#string

Stefan Sleijfer

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2016

Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility.

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

International variability in the reimbursement of cancer drugs by publically funded drug programs

A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells.

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.

Cross-comparison of cancer drug approvals at three international regulatory agencies.

Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments.

P304

825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2018.825

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maarten J. IJzerman

L W M M Terstappen

Hendrik Koffijberg

P577

2018-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29743945

http://www.w3.org/2001/XMLSchema#string

P932

5931813

http://www.w3.org/2001/XMLSchema#string